Page 92 - Sohini Das

Hyderabad-based Biological E joins hands with J&J for Covid-19 vaccine

The vaccine candidate is in phase 1/2a clinical trials

Covid-19: At Rs 2,800 per dose, Zydus launches cheapest remdesivir brand

Zydus plans to supply large quantities of the injectable drug in the market soon

Cipla tweaks management structure to mobilise second level of executives

Do these changes augur well for the future business growth plans? Analysts think so

India planning to create digital infra for distribution of Covid vaccine

A person close to the development said that of the various vaccine candidates under development now globally and in India, it is not yet clear how many shots would be required for each one

Mankind Pharma partners with South Korea's Daewoong for Covid drug

Will conduct clincial trials on anti-parasitic drug they claim is more effective than remdesivir

India weighs options in debate on who gets first shot of Covid-19 vaccine

Companies wait for government orders as top medical research group says health workers must get first inoculation

After showing signs of recovery in June, domestic pharma sales dip in July

Data shows that the Covid-19 crisis impacted the growth rate of the domestic market

Unique ID, data privacy give strength to Centre's digital health mission

Digitised health records could help collate and analyse data in a more comprehensive and 'real time' manner for policymaking

Serum Institute to provide Covid vaccine to 92 countries at Rs 250 a dose

Partners with Gavi, Gates Foundation, will provide 100 mn doses to Covax, a WHO initiative led by Gavi and CEPI

Cipla Q1 pre-tax profit jumps 20% to Rs 799 crore on strong revenues

Firm's domestic business did well, up 16% YoY during the quarter when Cipla launched licensed version of Gilead's remdesivir

How Mumbai raced to add more beds than patients after its June unlocking

Nearly half the bed capacity lies unutilised now

Coronavirus fears lead to sudden spike in pneumonia vaccine sales

many people have become sensitised to adult vaccination in the country as we await the first vaccine candidate against the SARS-CoV-2 virus

Domestic pharmaceutical industry to clock 4-6% growth in FY21: Icra

The domestic pharma industry has been posting slow growth numbers since March after the Covid-19 pandemic hit prescription generation

Dr Reddy's to launch Covid drugs remdesivir and favipiravir in August

Trying to boost acquired Wockhardt portfolio which saw sharp decline in sales during pandemic

Hetero joins long list of firms to launch Covid-19 drug favipiravir

Will sell its oral anitiviral for Rs 59 a pill, Cipla and DRL to launch soon

Trailing in the value chain: Domestic pharma's unfinished agenda

In the first of a 5-part series, we look at reasons keeping Indian pharma sector from becoming the best globally

Lessons learnt: Delhi, Mumbai show the way on how to tame the Covid curve

The drop in the curve, experts say, is partially because of the pandemic playing itself out, and partially because of the two cities finally getting their act together

Covid-19: Favipiravir triggers a price war; new brand launched at Rs 39

According to industry insiders, many more brands are lined up for launch, including one from Cipla

Adar Poonawalla: A rare risk-taking CEO with strong business acumen

Adar Poonawalla's Serum Institute has tied up with AstraZeneca-backed Oxford vaccine candidate for one billion doses which it will make for India and the GAVI vaccine alliance of 58 countries

Covid-19 crisis: Plasma transfusion is adjunct treatment; timing is key

The second of a two-part series looks at how effective plasma therapy is in the fight against Covid-19